Articles that tag RDHL but are mainly about other companies.
RHB-204, an optimized fixed-dose oral antibiotic combination, shows potential in both Crohn's disease and pulmonary NTM disease caused by MAC, with improved tolerability and patient adherence compared to predecessor RHB-104.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
